Solid Biosciences to Participate at Upcoming Investor Conferences
Rhea-AI Summary
Solid Biosciences (Nasdaq: SLDB), a precision genetic medicines developer for neuromuscular and cardiac diseases, has announced its participation in two upcoming investor conferences. Bo Cumbo, President and CEO, will be involved in both events:
1. H.C. Wainwright 26th Annual Global Investment Conference in New York, NY: Cumbo will participate in a fireside chat on September 10, 2024, at 9:30 am ET.
2. Baird 2024 Global Healthcare Conference in New York, NY: Cumbo will present on September 11, 2024, at 12:50 pm ET.
A live webcast of the H.C. Wainwright fireside chat will be available on the company's website, with a replay archived for 30 days. Institutional investors can arrange meetings with management through their H.C. Wainwright or Baird representatives.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – SLDB
On the day this news was published, SLDB gained 0.35%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CHARLESTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:
- H.C. Wainwright 26th Annual Global investment Conference – New York, NY
Bo Cumbo, President and CEO, will participate in a fireside chat on Tuesday, September 10, 2024, at 9:30 am ET.
- Baird 2024 Global Healthcare Conference – New York, NY
Mr. Cumbo will present on Wednesday, September 11, 2024, at 12:50 pm ET.
A live webcast of the H.C. Wainwright fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.
Institutional investors interested in meeting with management during the conferences may reach out to their H.C. Wainwright or Baird representatives.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
